tiprankstipranks
Advertisement
Advertisement

OKYO Stock Latest News

Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
The FlyOkyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
4d ago
OKYO
OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain
PremiumCompany Announcements
OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain
4d ago
6K
OKYO
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
PremiumCompany Announcements
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
5d ago
6K
OKYO
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain
PremiumCompany Announcements
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain
2M ago
6K
OKYO
OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver
PremiumCompany Announcements
OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver
2M ago
6K
OKYO
OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting
PremiumCompany AnnouncementsOKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting
3M ago
6K
OKYO
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial
Premium
Company Announcements
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial
4M ago
6K
OKYO
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3
Premium
Company Announcements
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3
4M ago
6K
OKYO
Okyo Pharma director John Brancaccio acquires 5,000 shares
PremiumThe Fly
Okyo Pharma director John Brancaccio acquires 5,000 shares
4M ago
OKYO
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress
PremiumCompany Announcements
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress
4M ago
6K
OKYO
Okyo Pharma CDO, director acquire shares
PremiumThe Fly
Okyo Pharma CDO, director acquire shares
4M ago
OKYO
Okyo Pharma reports results from Phase 2a trial of urcosimod
PremiumThe Fly
Okyo Pharma reports results from Phase 2a trial of urcosimod
4M ago
OKYO
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
PremiumCompany AnnouncementsOKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
4M ago
6K
OKYO
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
Premium
Company Announcements
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
5M ago
6K
OKYO
Okyo Pharma initiated with an Overweight at Piper Sandler
Premium
The Fly
Okyo Pharma initiated with an Overweight at Piper Sandler
5M ago
OKYO
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
PremiumCompany Announcements
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
5M ago
6K
OKYO
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
PremiumCompany Announcements
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
5M ago
6K
OKYO
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
PremiumThe Fly
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
5M ago
OKYO
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
PremiumCompany Announcements
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
5M ago
6K
OKYO
Okyo Pharma announces ordinary shares offering, no amount given
PremiumThe FlyOkyo Pharma announces ordinary shares offering, no amount given
5M ago
OKYO
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
Premium
Company Announcements
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
5M ago
6K
OKYO
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
Premium
Company Announcements
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
5M ago
6K
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >